Serum level of insulin-like growth factor-1 and insulin-like growth factor binding protein-3 in acute coronary syndromes and relationship with prognosis; [Akut Koroner Sendromlarda ̇ Insl̈in Benzeri Büyüme Faktörü-I ve ̇ Insülin Benzeri Büyüme Faktörü Baǧlayici Protein-3 Düzeyleri ve Prognozla ̇ Ilişkisi]

dc.contributor.authorŞekuri C.
dc.contributor.authorArslan Ö.
dc.contributor.authorÜtük O.
dc.contributor.authorBayturan Ö.
dc.contributor.authorOnur E.
dc.contributor.authorTezcan U.K.
dc.contributor.authorTavli T.
dc.date.accessioned2024-07-22T08:24:24Z
dc.date.available2024-07-22T08:24:24Z
dc.date.issued2004
dc.description.abstractObjective: The aim of the present study was to examine the levels of insulin-like growth factor (IGF-I) and binding protein-3 (IGFBP-3) in acute coronary syndrome (ACS) and their relationship with prognosis. Methods: Thirty patients with ACS (22 male, 8 female) were included in our study. Patient's population included 20 patients with ST elevation myocardial infarction (STEMI) and 10 with non-ST-elevation ACS. Death, re-infarction, revascularization and malignant arrhythmia were monitored during 3 months. Study group was compared with 20 healthy subjects (Controls). Blood samples were collected in the first 24 hours and at the end of third month. Serum IGF-I and IGFBP-3 levels were determined by radioimmunoassay method. Results: We found decreased level of IGF-I only in the STEMI group (105±84 ng/ml vs. 715±150 ng/ml, p<0.0001). There were no significant differences in IGFBP-3 levels between two groups. Serum IGF-I levels were significantly increased after 3rd month in the STEMI group (356±72 ng/ml vs. 105±84 ng/ml, p=0.025). There was no relationship between IGF-I, IGFBP-3 levels and cardiovascular events occurred during 90 days of follow-up. Conclusion: These data allows to suggest that significantly decreased level of IGF-I in STEMI group of ACSs can be used as a marker of myocardial necrosis. There was no relationship between IGF-I level and cardiovascular events occurred in 90 days, so this parameter can not be used as a negative prognostic factor.
dc.identifier.issn13028723
dc.identifier.urihttp://akademikarsiv.cbu.edu.tr:4000/handle/123456789/19962
dc.language.isoTurkish
dc.subjectCase-Control Studies
dc.subjectCholesterol
dc.subjectCholesterol, HDL
dc.subjectCholesterol, LDL
dc.subjectFemale
dc.subjectHumans
dc.subjectInsulin-Like Growth Factor Binding Protein 3
dc.subjectInsulin-Like Growth Factor I
dc.subjectMale
dc.subjectMiddle Aged
dc.subjectMyocardial Infarction
dc.subjectPrognosis
dc.subjectSeverity of Illness Index
dc.subjectTriglycerides
dc.subjectTurkey
dc.subjectsomatomedin binding protein 3
dc.subjectsomatomedin C
dc.subjectcholesterol
dc.subjecthigh density lipoprotein cholesterol
dc.subjectlow density lipoprotein cholesterol
dc.subjectsomatomedin binding protein 3
dc.subjectsomatomedin C
dc.subjecttriacylglycerol
dc.subjectadult
dc.subjectaged
dc.subjectarticle
dc.subjectblood analysis
dc.subjectclinical article
dc.subjectcomparative study
dc.subjectcontrolled study
dc.subjectdeath
dc.subjectdisease marker
dc.subjectfemale
dc.subjectfollow up
dc.subjectheart arrhythmia
dc.subjectheart infarction
dc.subjectheart muscle ischemia
dc.subjectheart muscle necrosis
dc.subjectheart reinfarction
dc.subjecthuman
dc.subjectmale
dc.subjectpatient monitoring
dc.subjectpopulation research
dc.subjectprognosis
dc.subjectprotein blood level
dc.subjectradioimmunoassay
dc.subjectrevascularization
dc.subjectST segment elevation
dc.subjectstatistical significance
dc.subjectblood
dc.subjectcase control study
dc.subjectheart infarction
dc.subjecthospitalization
dc.subjectmetabolism
dc.subjectmiddle aged
dc.subjectmortality
dc.subjectTurkey (republic)
dc.titleSerum level of insulin-like growth factor-1 and insulin-like growth factor binding protein-3 in acute coronary syndromes and relationship with prognosis; [Akut Koroner Sendromlarda ̇ Insl̈in Benzeri Büyüme Faktörü-I ve ̇ Insülin Benzeri Büyüme Faktörü Baǧlayici Protein-3 Düzeyleri ve Prognozla ̇ Ilişkisi]
dc.typeArticle

Files